Maternal asthma medication use and the risk of gastroschisis

Shao Lin; Jean Pierre W Munsie; Michele L Herdt-Losavio; Erin Bell; Charlotte Druschel; Paul A Romitti; Richard Olney; National Birth Defects Prevention Study

doi:10.1093/aje/kwn098

Back

Maternal asthma medication use and the risk of gastroschisis

Journal article

Open access

Peer reviewed

Maternal asthma medication use and the risk of gastroschisis

Shao Lin, Jean Pierre W Munsie, Michele L Herdt-Losavio, Erin Bell, Charlotte Druschel, Paul A Romitti, Richard Olney and National Birth Defects Prevention Study

American journal of epidemiology, Vol.168(1), pp.73-79

07/01/2008

DOI: 10.1093/aje/kwn098

PMCID: PMC6067822

PMID: 18436535

Files and links (1)

url

https://doi.org/10.1093/aje/kwn098View

Published (Version of record) Open Access

Abstract

The objective of this study was to examine the association between maternal asthma medication use during the periconceptional period and the risk of gastroschisis. In this case-control study, the authors used data on deliveries enrolled in the National Birth Defects Prevention Study (1997-2002) from eight collaborating centers. The cases included 381 infants with isolated gastroschisis, and the controls were 4,121 liveborn infants without malformations. The asthma medications used during the periconceptional period (1 month prepregnancy through the third pregnancy month) were divided into two groups, antiinflammatory and bronchodilator, and analyzed separately. Users of multiple asthma medications during the periconceptional period were also examined. Logistic regression was used to estimate odds ratios and 95% confidence intervals while controlling for maternal age, race/ethnicity, education, smoking, folic acid/vitamin use, and other vasoactive medications. Maternal bronchodilator use showed an elevated statistically significant risk of gastroschisis (adjusted odds ratio = 2.06, 95% confidence interval: 1.19, 3.59). No significant association was found between maternal use of asthma antiinflammatory medications and gastroschisis. Because information on maternal asthma status/severity was not available, the effects of disease on the risk of gastroschisis cannot be ruled out. Additional research is needed in determining whether a real risk exists and for guiding asthma treatment.

Bronchodilator Agents - therapeutic use

Life Style

Bronchodilator Agents - administration & dosage

Maternal-Fetal Exchange

United States

Humans

Logistic Models

Male

Asthma - drug therapy

Case-Control Studies

Pregnancy Complications - drug therapy

Gastroschisis - chemically induced

Pregnancy

Anti-Inflammatory Agents - adverse effects

Anti-Inflammatory Agents - therapeutic use

Adult

Anti-Inflammatory Agents - administration & dosage

Female

Interviews as Topic

Bronchodilator Agents - adverse effects

Infant, Newborn

Maternal Welfare

Details

Title: Subtitle: Maternal asthma medication use and the risk of gastroschisis
Creators: Shao Lin - Center for Environmental Health, New York State Department of Health, Troy, NY 12180, USA. sxl05@health.state.ny.us
Jean Pierre W Munsie
Michele L Herdt-Losavio
Erin Bell
Charlotte Druschel
Paul A Romitti
Richard Olney
National Birth Defects Prevention Study
Resource Type: Journal article
Publication Details: American journal of epidemiology, Vol.168(1), pp.73-79
Publisher: United States
DOI: 10.1093/aje/kwn098
PMID: 18436535
PMCID: PMC6067822
ISSN: 1476-6256
eISSN: 1476-6256
Grant note: U50CCU213244 / PHS HHS U01 DD000487 / NCBDD CDC HHS U50 DD713238 / NCBDD CDC HHS
Language: English
Date published: 07/01/2008
Academic Unit: Epidemiology; Biostatistics
Record Identifier: 9983995003402771

Metrics

19 Record Views

65 Times Cited - Web of Science